Targeting TGF-β1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis

Inflammatory Bowel Diseases

Volumn 16, Issue 6, 2010, Pages 1040-1050

  Ma, Yanbing ^a   Guan, Qingdong ^a   Bai, Aiping ^a   Weiss, Carolyn R ^a   Hillman, China Li ^a   Ma, Allan ^a   Zhou, Gang ^a   Qing, Gefei ^a   Peng, Zhikang ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Inflammatory bowel disease; Mouse; TGF 1; TNBS; Vaccine

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 23; TRANSFORMING GROWTH FACTOR BETA1; TRINITROBENZENESULFONIC ACID; VACCINE; RECOMBINANT VACCINE; SMAD3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CHRONIC DISEASE; COLITIS; COLON; CONTROLLED STUDY; DRUG SCREENING; ENTERITIS; FEMALE; HISTOLOGY; IMMUNIZATION; INTESTINAL FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS LIKE AGENT; WEIGHT GAIN; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FIBROSIS; IMMUNOLOGY; LYMPH NODE; MESENTERY; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; COLITIS; FEMALE; FIBROSIS; IMMUNOGLOBULIN G; INTERLEUKIN-17; INTERLEUKIN-23; LYMPH NODES; MESENTERY; MICE; MICE, INBRED BALB C; PHOSPHORYLATION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TRINITROBENZENESULFONIC ACID; VACCINES, SYNTHETIC;

EID: 77952678563     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21167     Document Type: Article

References (46)

1. Burke JP, Mulsow JJ, O'Keane C, et al. Fibrogenesis in Crohn's disease. Am J Gastroenterol. 2007;102:439-448.
2. Rieder F, Fiocchi C. Intestinal fibrosis in IBD - a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol. 2009;6:228-235.
3. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007;117:524-529.
4. Verrecchia F, Mauviel A. Transforming growth factor-beta and fibrosis. World J Gastroenterol. 2007;13:3056-3062.
5. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199-210.
6. Makinde T, Murphy RF, Agrawal DK. The regulatory role of TGF-beta in airway remodeling in asthma. Immunol Cell Biol. 2007;85:348-356. (Pubitemid 47035605)
7. Stawowy P, Margeta C, Kallisch H, et al. Regulation of matrix metalloproteinase MT1-MMP/MMP-2 in cardiac fibroblasts by TGF-beta1 involves furin-convertase. Cardiovasc Res. 2004;63:87-97. (Pubitemid 38759813)
8. McKaig BC, McWilliams D, Watson SA, et al. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol. 2003;162:1355-1360. (Pubitemid 36350679)
9. Mulsow JJ, Watson RW, Fitzpatrick JM, et al. Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. Ann Surg. 2005;242:880-887; discussion 887-889.
10. Cutroneo KR. TGF-beta-induced fibrosis and SMAD signaling: oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring. Wound Repair Regen. 2007;15(suppl 1):S54-60.
11. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, et al. TGF-beta signaling in vascular fibrosis. Cardiovasc Res. 2007;74:196-206.
12. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med. 2006;10:76-99. (Pubitemid 44874293)
13. Di Sabatino A, Jackson CL, Pickard KM, et al. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut. 2009;58:777-789.
14. McKaig BC, Hughes K, Tighe PJ, et al. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol. 2002;282:C172-182.
15. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology. 1996;110:975-984. (Pubitemid 26113734)
16. Fichtner-Feigl S, Young CA, Kitani A, et al. IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fi- brosis in chronic TNBS colitis. Gastroenterology. 2008;135:2003-2013, 2013 e2001-2007.
17. Fichtner-Feigl S, Fuss IJ, Young CA, et al. Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol. 2007;178:5859-5870.
18. Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12:99-106.
19. Vallance BA, Gunawan MI, Hewlett B, et al. TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol Gastrointest Liver Physiol. 2005;289:G116-128.
20. Prud'homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest. 2007;87:1077-1091.
21. Zagury D, Le Buanec H, Bizzini B, et al. Active versus passive anticytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev. 2003;14:123-137. (Pubitemid 36389526)
22. Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601-609. (Pubitemid 32777740)
23. Monteleone G, Mann J, Monteleone I, et al. A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem. 2004;279:3925-3932. (Pubitemid 38198975)
24. Boirivant M, Pallone F, Di Giacinto C, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology. 2006;131:1786-1798. (Pubitemid 44958514)
25. Spohn G, Keller I, Beck M, et al. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol. 2008;38:877-887.
26. Ma Y, Hayglass KT, Becker AB, et al. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am J Respir Crit Care Med. 2007;176:439-445. (Pubitemid 47358097)
27. Ma Y, HayGlass KT, Becker AB, et al. Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice. Allergy. 2007;62:675-682. (Pubitemid 46763447)
28. Spohn G, Guler R, Johansen P, et al. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol. 2007;178:7450-7457. (Pubitemid 46847473)
29. Uyttenhove C, Sommereyns C, Theate I, et al. Anti-IL-17A autovaccination prevents clinical and histological manifestations of experimental autoimmune encephalomyelitis. Ann N Y Acad Sci. 2007;1110:330-336. (Pubitemid 350043022)
30. Dalum I, Butler DM, Jensen MR, et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol. 1999;17:666-669. (Pubitemid 29316144)
31. Le Buanec H, Delavallee L, Bessis N, et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci USA. 2006;103:19442-19447. (Pubitemid 46026050)
32. Rohn TA, Jennings GT, Hernandez M, et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol. 2006;36:2857-2867. (Pubitemid 44782559)
33. Capini CJ, Bertin-Maghit SM, Bessis N, et al. Active immunization against murine TNFalpha peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. Vaccine. 2004;22:3144-3153. (Pubitemid 39037218)
34. Nardin EH, Oliveira GA, Calvo-Calle JM, et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun. 2004;72:6519-6527.
35. Abe M, Harpel JG, Metz CN, et al. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem. 1994;216:276-284. (Pubitemid 24076008)
36. Moriyama I, Ishihara S, Rumi MA, et al. Decoy oligodeoxynucleotide targeting activator protein-1 (AP-1) attenuates intestinal inflammation in murine experimental colitis. Lab Invest. 2008;88:652-663. (Pubitemid 351733283)
37. Korn T, Oukka M, Kuchroo V, et al. Th17 cells: effector T cells with inflammatory properties. Semin Immunol. 2007;19:362-371. (Pubitemid 351274046)
38. McGeachy MJ, Cua DJ. The link between IL-23 and Th17 cell-mediated immune pathologies. Semin Immunol. 2007;19:372-376.
39. Maloy KJ. The interleukin-23/interleukin-17 axis in intestinal inflammation. J Intern Med. 2008;263:584-590.
40. Zhang Z, Zheng M, Bindas J, et al. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis. 2006;12:382-388. (Pubitemid 43756199)
41. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233-240. (Pubitemid 40189432)
42. Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179-189. (Pubitemid 43214587)
43. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685-700. (Pubitemid 36724933)
44. Feng XH, Derynck R. Specificity and versatility in TGF-beta signaling through Smads. Annu Rev Cell Dev Biol. 2005;21:659-693. (Pubitemid 41740650)
45. Monteleone G, Pallone F, MacDonald TT. Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol. 2004;25:513-517. (Pubitemid 39208348)
46. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med. 1999;341:1966-1973.